Overview
- Sanofi confirmed on Thursday, July 23 that it is experiencing a period of intermittent supply for Lantus SoloStar prefilled pens and called the situation temporary.
- The company attributes the disruption to increased demand driven by broader market dynamics and says it is accelerating production, expediting incoming stock and managing allocations.
- Sanofi emphasized the problem is limited to the SoloStar pen format and that Lantus U-100 vials and the Toujeo U-300 formulation remain available as alternatives.
- Pharmacies including CVS report intermittent Lantus availability over recent months and say pharmacy teams are working with prescribers to identify substitutes for affected patients.
- Clinicians warn patients not to skip insulin, advise immediate contact with health providers to arrange alternatives or generics, and note the FDA has not listed Lantus on its Drug Shortages Database.